Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Medibank (ASX:MPL) Share Price On Watch After FY20 Profit Warning

The Medibank (ASX:MPL) share price will be on watch this morning after giving a FY20 profit warning. 

The Medibank (ASX: MPL) share price will be on watch this morning after giving a FY20 profit warning.

Medibank is the largest listed private health insurer in Australia with its Medibank and AHM brands. It has been operating for over 40 years and has around 1.8 million policyholders & 3.7 million customers. The company is headquartered in Melbourne.

Medibank’s FY20 Update

The large private health insurer is updating the FY20 outlook it gave to investors at its FY19 result.

Since August, Medibank has been experiencing higher than expected claims which has resulted in a $21 million under provision from the 30 June 2019 claims reserve.

Medibank disclosed that this now indicates that the underlying claims growth per policy unit was 2.4% in FY19, not the 2% which was reported at the full year. This increase is now expected to continue throughout FY20.

The higher claims have been driven higher by a number of factors, particularly because of higher private hospital payments due to an increase of the average benefit size with elevated prosthesis costs.

Medibank said the industry claims environment remains challenging, which is why the company is focused on growing policyholder numbers. For the first quarter net resident policyholder growth was around 0.6%, or 10,000 policyholders. This is almost double the growth rate a year ago in the first quarter of FY19.

Management are confident that the company is on track to stabilise its policyholder numbers by the end of FY20 and grow in FY21.

Costs is another area that Medibank can give attention, which is why management expenses are expected to be around $545 million this year compared to $560.1 million in FY19, which would represent an improvement of 2.7%, or $15.1 million in dollar terms.

Medibank used the opportunity to call for further government reform because private health insurers are having to juggle premiums being affordable while costs keep rising within the health system.

[ls_content_block id=”14946″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content